Evidence map›Paper›PMID 42356477›Full record

ReviewPharmaceuticals (Basel, Switzerland)2026

Advancements in Dual-Load Antibody-Drug Conjugates and Challenges with Quality Analysis.

Xiaojuan Yu, Xiao Ke, Yao Tang, Tao Tang, Yongbo Ni, Luyun Guo, Yongfei Cui, Yuting Mei, Gangling Xu, Gang Wu and 11 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pharmaceuticals (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Xiaojuan YuNational Institutes for Food and Drug Control, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, State Key Laboratory of Drug Regulatory Science, Beijing 102629, China.
Xiao KeChengdu Kanghong Pharmaceutical Group Co., Ltd., Chengdu 610037, China.
Yao TangSichuan Institute for Drug Control, NMPA Center for Innovation and Research in Regulatory Science, Chengdu 611731, China.
Tao TangSichuan Institute for Drug Control, NMPA Center for Innovation and Research in Regulatory Science, Chengdu 611731, China.
Yongbo NiNational Institutes for Food and Drug Control, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, State Key Laboratory of Drug Regulatory Science, Beijing 102629, China.
Luyun GuoNational Institutes for Food and Drug Control, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, State Key Laboratory of Drug Regulatory Science, Beijing 102629, China.
Yongfei CuiNational Institutes for Food and Drug Control, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, State Key Laboratory of Drug Regulatory Science, Beijing 102629, China.
Yuting MeiNational Institutes for Food and Drug Control, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, State Key Laboratory of Drug Regulatory Science, Beijing 102629, China.
Gangling XuNational Institutes for Food and Drug Control, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, State Key Laboratory of Drug Regulatory Science, Beijing 102629, China.
Gang WuNational Institutes for Food and Drug Control, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, State Key Laboratory of Drug Regulatory Science, Beijing 102629, China.
Yalan YangNational Institutes for Food and Drug Control, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, State Key Laboratory of Drug Regulatory Science, Beijing 102629, China.
Maoqin DuanNational Institutes for Food and Drug Control, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, State Key Laboratory of Drug Regulatory Science, Beijing 102629, China.ORCID 0000-0002-0865-029X
Jialiang DuNational Institutes for Food and Drug Control, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, State Key Laboratory of Drug Regulatory Science, Beijing 102629, China.ORCID 0000-0003-1495-5521
Meng LiNational Institutes for Food and Drug Control, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, State Key Laboratory of Drug Regulatory Science, Beijing 102629, China.
Jiao TangChengdu Kanghong Pharmaceutical Group Co., Ltd., Chengdu 610037, China.
Shijun YinChengdu Kanghong Pharmaceutical Group Co., Ltd., Chengdu 610037, China.
Jiali ZuoChengdu Kanghong Pharmaceutical Group Co., Ltd., Chengdu 610037, China.
Yanhua XuChengdu Kanghong Pharmaceutical Group Co., Ltd., Chengdu 610037, China.
Yonghao ZhaoChengdu Kanghong Pharmaceutical Group Co., Ltd., Chengdu 610037, China.
Yan LiSichuan Institute for Drug Control, NMPA Center for Innovation and Research in Regulatory Science, Chengdu 611731, China.
Chuanfei YuNational Institutes for Food and Drug Control, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, State Key Laboratory of Drug Regulatory Science, Beijing 102629, China.

Funding

Prevention and Control of Emerging and Major Infectious  Diseases-National Science and Technology Major Project 2025ZD01904200State Key Laboratory of Drug Regulatory Science Project 2025SKLDRS0318
6 · The paper itself

Abstract

Antibody-drug conjugates (ADCs) are a pivotal technology for precision cancer therapy, harnessing the synergistic effects of antibody targeting and toxin delivery. However, traditional ADCs encounter limitations in efficacy that stem from tumor resistance, heterogeneity, and intense target competition. Dual-payload ADCs (DP-ADCs) represent a promising solution to these challenges, as they leverage dual mechanisms of action that mitigate acquired drug resistance and enhance adaptability to tumor heterogeneity. The complex structure of DP-ADCs presents substantial quality control hurdles. In this manuscript, we review the current payload selection and conjugation strategies of DP-ADCs and examine recent advances in quality control research. Specifically, we analyze the analytical challenges related to the quantification of free toxins, the determination of the total antibody content, and the characterization of the drug-to-antibody ratio and its distribution. Ultimately, the aim of this work is to provide valuable guidance for future DP-ADC quality control analyses to facilitate their clinical translation and application.

Indexed as

analytical methodsdrug-to-antibody ratiodual-payload antibody–drug conjugatesliquid chromatography–mass spectrometryquality control

Identifiers

PMID42356477
PMCPMC13305441

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.